Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane with metronomic capecitabine versus exemestane alone for second-line metastatic breast cancer
ChiCTR1800018415Phase 4Not yet recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Oct 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in breast cancer comparing Exemestane with Exemestane + metronomic capecitabine (2 arms). Primary endpoint: Progression-free survival. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
exemestanecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800018415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018415.